NEWSROOM

ENBIOSIS, a Turkish enterprise operating in the field of health technologies, has achieved significant success in its studies on early diagnosis technologies. The initiative explained that it was able to detect colon cancer from stool samples with an accuracy of 89%.

*** This release is originally published in Turkish.
Google Translate Application translates the content you see on this page.***

ISTANBUL (TR) - Intestinal diseases, and Turkey are among the most common health problems in the world. The main ones are irritable bowel syndrome, ulcerative colitis, Crohn's disease and colon cancer. Early diagnosis, which plays a decisive role in the success of treatment in intestinal diseases, as in all diseases, is of vital importance especially for colon cancer patients. Turkey World Health Organization's cancer in both men according to statistics, one of the three most common types of cancer in both women colon cancer, a threat to one out of every 20 people. Promising developments are taking place in the studies conducted for early diagnosis.

ENBIOSIS, the Turkish biotechnology initiative that develops personalized health solutions for many problems such as obesity, diabetes, cardiological diseases and chronic intestinal diseases by analyzing the microorganisms in the human intestine, has achieved a significant success in the early diagnosis technologies studies it conducts. Biotechnology initiative announced that it can detect colon cancer with 89% accuracy with only stool samples, thanks to the genetic-based microbiome analysis it has developed.

95% accurate diagnosis of Ulcerative Colitis and Crohn's disease

Making a statement on the subject, ENBIOSIS CTO Dr. Özkan Ufuk Nalbantoğlu stated that they obtained successful results for the early diagnosis of not only colon cancer but also chronic intestinal diseases.

Nalbantoğlu said, “Scientific studies conducted on the intestinal microbiome for more than ten years reveal that microorganisms living in the large intestine play a role in many intestinal disorders. Microbiome analysis, which will reveal these disease risks with only a stool analysis, is a technology that has just started to emerge in the world. As ENBIOSIS, we made a significant progress in the detection of inflammatory bowel disease, irritable bowel syndrome and colorectal cancer diseases with the genetic-based microbiome analysis we developed within the scope of our R&D studies on this subject. According to the clinical data we have, we can detect colon cancer with 89%, irritable bowel syndrome with 96%, ulcerative colitis and Crohn's disease with 95% accuracy.”

Early detection will be possible with only a stool sample

Underlining that with their work, the bacteria in the human intestine have demonstrated the importance of prevention from diseases as well as diagnosis and treatment support approaches, Nalbantoğlu said, “We know that many gastrointestinal disorders are reflected in the composition of the intestinal microbiome. However, it is not possible to understand them from the state of one or a few microorganisms, so they need to be examined at the system and ecosystem level. The technology we have developed is based on an algorithm that will analyze all genes in the microbiome and identify the disease. When this technology is implemented, early detection of intestinal infections, chronic intestinal diseases and bowel cancers will be possible with only stool samples.”